Ask
Search
My library
ORKG

ORKG Ask

Our mission is to organize scholarly knowledge and make it accessible to humans and machines.

About

About ORKG Ask
Report issue
Statistics
Contact

Legal

Terms of use
Data protection (sheet)
Imprint
Accessibility
License

Technical

We
open source
System status
Changelog
Frontend: v1.41.0
Backend: v1.13.4

We use cookies to provide a better user experience.

Data Protection

Azacitidine in AML: a treatment option?

Huls, G.A.

Publication date

January 2015

DOI

10.1182/blood-2015-06-648071

Publisher

American Society of Hematology

ISSN

0006-4971

Citation count (estimate)

9

Abstract

Contains fulltext : 151961.pdf (publisher's version ) (Closed access)In this issue of Blood, Dombret et al report the final analysis of the international phase 3 study of azacitidine vs conventional care regimens in older (>/=65 years), newly diagnosed acute myeloid leukemia (AML) patients with >30% bone marrow blasts and white blood cell (WBC) counts </=15 x 109/L (AZA-AML-001 study)

Extracted data

Related items

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Lisa Pleyer

February 2017

We recently published a clinically-meaningful improvement in median overall survival (OS) for patien...

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.

Helm, L.H. van der
Scheepers, E.R.
Veeger, N.J.
Daenen, S.M.G.J.
Mulder, A.B.
Berg, E. van den
Vellenga, E.
Huls, G.A.

January 2013

BACKGROUND: Treatment options in older acute myeloid leukaemia (AML) patients include intensive chem...

The role of azacitidine in the management of myelodysplastic syndromes (MDS)

KS G&amp
C M&amp
C Peschel

October 2009

KS G&ouml;tze, C M&uuml;ller-Thomas, C PeschelDepartment of Medicine, Hematology/Oncology, T...

Azacitidine in AML: a treatment option?

Huls, G.A.

January 2015

In this issue of Blood, Dombret et al report the final analysis of the international phase 3 study o...

Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes

Moreno Vanegas Y
Badar T

December 2022

Yenny Moreno Vanegas, Talha Badar Division of Hematology-Oncology and Blood and Marrow Transplantati...

Azacitidine for the treatment of patients with acute myeloid leukemia : Report of 82 patients enrolled in an Italian compassionate program

Maurillo L
Venditti A
Spagnoli A
Ferrero D
Oliva E
Lunghi M
D'Arco AM
Levis A
Pastore D
Di Renzo N
Santagostino A
Pavone V
Buccisano F
Musto P.
GAIDANO, Gianluca

January 2012

BACKGROUND: The efficacy of azacitidine for the treatment of high-risk myelodysplastic syndromes ha...

Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML

Tenti, Elena
Papayannidis, Cristina
Marconi, Giovanni
Parisi, Sarah
Simonetti, Giorgia
Paolini, Stefania
Sartor, Chiara
Ottaviani, Emanuela
Testoni, Nicoletta
Martinelli, Giovanni

January 2016

Introduction: Therapy for acute myeloid leukemia (AML) in elderly populations (>65\ua0years) is stil...

ORIGINAL ARTICLE Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry

Georg Theiler
S. Burgstaller
J. Thaler
M. Girschikofsky
S. Machherndl-sp
W. Linkesch :g. Theiler
R. Stauder
M. Pfeilstocker
M. Schreder

January 2014

# The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Data o...

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Dombret H.
Seymour J. F.
Butrym A.
Wierzbowska A.
Selleslag D.
Jang J. H.
Kumar R.
Cavenagh J.
Schuh A. C.
Candoni A.
Recher C.
Sandhu I.
Del Castillo T. B.
Al-Ali H. K.
Martinelli G.
Falantes J.
Noppeney R.
Stone R. M.
Minden M. D.
McIntyre H.
Songer S.
Lucy L. M.
Beach C. L.
Dohner H.

January 2015

This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs...

Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

van der Helm, L.H.
Veeger, N.J.G.M.
van Marwijk Kooy, M.
Beeker, A.
de Weerdt, O.
de Groot, M.
Alhan, C.
Hoogendoorn, M.
Laterveer, L.
van de Loosdrecht, A.A.
Koedam, J.
Vellenga, E.
Huls, G.

January 2013

The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-3...

Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience

Ar, Cem
Salihoglu, Ayse
Atesoglu, Elif Birtas
Ferhanoglu, Burhan
Tuzuner, Nukhet
Ozbalak, Murat
Cetiner, Mustafa
Bekoz, Huseyin

January 2012

Myelodysplastic syndrome (MDS) represents a heterogeneous group of potentially malignant diseases of...

Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP)

DELIA, MARIO
Carluccio, Paola
BUQUICCHIO, CATERINA
Vergine, Carolina
GRECO, GIUSEPPINA
Amurri, Barbara
Melpignano, Angela
Melillo, Lorella
Cascavilla, Nicola
Guarini, Attilio
Capalbo, Silvana
Tarantini, Giuseppe
Mazza, Patrizio
Pavone, Vincenzo
Di Renzo, Nicola
SPECCHIA, Giorgina

January 2015

The optimal treatment of older patients (>65 years) with acute myeloid leukemia (AML) remains challe...

Article Reference

Jakob R. Passweg
Thomas Pabst
Sabine Blum
Mario Bargetzi
Qiyu Li
Dominik Heim
Georg Stussi
Michael Gregor
Leda Leoncini
Rine Meyer-monard
Peter Brauchli
Yves Chal

September 2016

Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07) P...

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

van der Helm, L.H.
Scheepers, E.R.M.
Veeger, N.J.G.M.
Daenen, S.M.G.J.
Mulder, A.B.
van den Berg, E.
Vellenga, E.
Huls, G.

January 2013

Background: Treatment options in older acute myeloid leukaemia (AML) patients include intensive chem...

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Nikolova D.
Yordanov A.
Radinov A.

October 2021

Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderl...

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Lisa Pleyer

February 2017

We recently published a clinically-meaningful improvement in median overall survival (OS) for patien...

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.

Helm, L.H. van der
Scheepers, E.R.
Veeger, N.J.
Daenen, S.M.G.J.
Mulder, A.B.
Berg, E. van den
Vellenga, E.
Huls, G.A.

January 2013

BACKGROUND: Treatment options in older acute myeloid leukaemia (AML) patients include intensive chem...

The role of azacitidine in the management of myelodysplastic syndromes (MDS)

KS G&amp
C M&amp
C Peschel

October 2009

KS G&ouml;tze, C M&uuml;ller-Thomas, C PeschelDepartment of Medicine, Hematology/Oncology, T...

Azacitidine in AML: a treatment option?

Huls, G.A.

January 2015

In this issue of Blood, Dombret et al report the final analysis of the international phase 3 study o...

Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes

Moreno Vanegas Y
Badar T

December 2022

Yenny Moreno Vanegas, Talha Badar Division of Hematology-Oncology and Blood and Marrow Transplantati...

Azacitidine for the treatment of patients with acute myeloid leukemia : Report of 82 patients enrolled in an Italian compassionate program

Maurillo L
Venditti A
Spagnoli A
Ferrero D
Oliva E
Lunghi M
D'Arco AM
Levis A
Pastore D
Di Renzo N
Santagostino A
Pavone V
Buccisano F
Musto P.
GAIDANO, Gianluca

January 2012

BACKGROUND: The efficacy of azacitidine for the treatment of high-risk myelodysplastic syndromes ha...

Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML

Tenti, Elena
Papayannidis, Cristina
Marconi, Giovanni
Parisi, Sarah
Simonetti, Giorgia
Paolini, Stefania
Sartor, Chiara
Ottaviani, Emanuela
Testoni, Nicoletta
Martinelli, Giovanni

January 2016

Introduction: Therapy for acute myeloid leukemia (AML) in elderly populations (>65\ua0years) is stil...

ORIGINAL ARTICLE Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry

Georg Theiler
S. Burgstaller
J. Thaler
M. Girschikofsky
S. Machherndl-sp
W. Linkesch :g. Theiler
R. Stauder
M. Pfeilstocker
M. Schreder

January 2014

# The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Data o...

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Dombret H.
Seymour J. F.
Butrym A.
Wierzbowska A.
Selleslag D.
Jang J. H.
Kumar R.
Cavenagh J.
Schuh A. C.
Candoni A.
Recher C.
Sandhu I.
Del Castillo T. B.
Al-Ali H. K.
Martinelli G.
Falantes J.
Noppeney R.
Stone R. M.
Minden M. D.
McIntyre H.
Songer S.
Lucy L. M.
Beach C. L.
Dohner H.

January 2015

This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs...

Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

van der Helm, L.H.
Veeger, N.J.G.M.
van Marwijk Kooy, M.
Beeker, A.
de Weerdt, O.
de Groot, M.
Alhan, C.
Hoogendoorn, M.
Laterveer, L.
van de Loosdrecht, A.A.
Koedam, J.
Vellenga, E.
Huls, G.

January 2013

The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-3...

Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience

Ar, Cem
Salihoglu, Ayse
Atesoglu, Elif Birtas
Ferhanoglu, Burhan
Tuzuner, Nukhet
Ozbalak, Murat
Cetiner, Mustafa
Bekoz, Huseyin

January 2012

Myelodysplastic syndrome (MDS) represents a heterogeneous group of potentially malignant diseases of...

Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP)

DELIA, MARIO
Carluccio, Paola
BUQUICCHIO, CATERINA
Vergine, Carolina
GRECO, GIUSEPPINA
Amurri, Barbara
Melpignano, Angela
Melillo, Lorella
Cascavilla, Nicola
Guarini, Attilio
Capalbo, Silvana
Tarantini, Giuseppe
Mazza, Patrizio
Pavone, Vincenzo
Di Renzo, Nicola
SPECCHIA, Giorgina

January 2015

The optimal treatment of older patients (>65 years) with acute myeloid leukemia (AML) remains challe...

Article Reference

Jakob R. Passweg
Thomas Pabst
Sabine Blum
Mario Bargetzi
Qiyu Li
Dominik Heim
Georg Stussi
Michael Gregor
Leda Leoncini
Rine Meyer-monard
Peter Brauchli
Yves Chal

September 2016

Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07) P...

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

van der Helm, L.H.
Scheepers, E.R.M.
Veeger, N.J.G.M.
Daenen, S.M.G.J.
Mulder, A.B.
van den Berg, E.
Vellenga, E.
Huls, G.

January 2013

Background: Treatment options in older acute myeloid leukaemia (AML) patients include intensive chem...

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Nikolova D.
Yordanov A.
Radinov A.

October 2021

Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderl...

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Lisa Pleyer

February 2017

We recently published a clinically-meaningful improvement in median overall survival (OS) for patien...

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.

Helm, L.H. van der
Scheepers, E.R.
Veeger, N.J.
Daenen, S.M.G.J.
Mulder, A.B.
Berg, E. van den
Vellenga, E.
Huls, G.A.

January 2013

BACKGROUND: Treatment options in older acute myeloid leukaemia (AML) patients include intensive chem...

The role of azacitidine in the management of myelodysplastic syndromes (MDS)

KS G&amp
C M&amp
C Peschel

October 2009

KS G&ouml;tze, C M&uuml;ller-Thomas, C PeschelDepartment of Medicine, Hematology/Oncology, T...